FDA Grants First Approvals for Generic Versions of Lyrica
TUESDAY, July 23, 2019 -- Nine drug companies have received approval for the first generic versions of Lyrica (pregabalin), the U.S. Food and Drug Administration announced. The generic versions of Lyrica have been approved to manage neuropathic... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - July 23, 2019 Category: General Medicine Source Type: news

Pfizer ’s Lyrica officially drops off the patent cliff
It was great while it lasted. But Pfizer ’s blockbuster drug, Lyrica, is now officially facing generics competition. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - July 22, 2019 Category: Pharmaceuticals Source Type: news

FDA Approves First Generics of Lyrica
July 22, 2019 -- On July 19, the U.S. Food and Drug Administration approved multiple applications for first generics of Lyrica (pregabalin) for the management of neuropathic pain associated with diabetic peripheral neuropathy, for the management of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 22, 2019 Category: Pharmaceuticals Source Type: news

FDA approves 9 generic versions of nerve pain drug Lyrica
FDA approves first generic copies of a popular pill for nerve pain (Source: ABC News: Health)
Source: ABC News: Health - July 22, 2019 Category: Consumer Health News Tags: Health Source Type: news

FDA Grants First Approvals for Generic Versions of Lyrica
MONDAY, July 22, 2019 -- Nine drug companies have received approval for the first generic versions of Lyrica (pregabalin), the U.S. Food and Drug Administration announced today. The generic versions of Lyrica have been approved to manage neuropathic... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 22, 2019 Category: Pharmaceuticals Source Type: news

FDA Approves First Lyrica Generics FDA Approves First Lyrica Generics
The US FDA has approved multiple applications for the first generics of pregabalin (Lyrica) for the management of neuropathic pain.FDA Approvals (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - July 22, 2019 Category: Internal Medicine Tags: Neurology & Neurosurgery News Alert Source Type: news

FDA approves first generics of Lyrica
On July 19, the U.S. Food and Drug Administration approved multiple applications for first generics of Lyrica (pregabalin) for the management of neuropathic pain associated with diabetic peripheral neuropathy, for the management of postherpetic neuralgia, as an adjunctive therapy for the treatment of partial onset seizures in patients 17 years of age and older, for the management of fibromyalgia, and for the management of neuropathic pain associated with spinal cord injury. (Source: World Pharma News)
Source: World Pharma News - July 22, 2019 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Gabapentinoids used Off-label for Pain: Effective or Erroneous?
Off-label gabapentin and pregabalin prescribing for pain is widespread; the opioid crisis may be to blame. But does science support the trend? Find out with these 10 questions. (Source: ConsultantLive)
Source: ConsultantLive - June 21, 2019 Category: Internal Medicine Authors: Steven A. King, MD, MS Tags: Pain Source Type: news

Common nerve pain drug linked to suicidal behavior, overdose
(Reuters Health) - A class of medications used for nerve and muscle pain, including the popular drug Lyrica, increases users' risks for suicidal behavior, unintentional overdoses, injuries and car accidents - and the risks are particularly high for teens and young adults, new research shows. (Source: Reuters: Health)
Source: Reuters: Health - June 17, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Epilepsy Drug Linked to Suicide Risk in Young
The medicine, pregabalin (Lyrica), comes from a class of drugs called gabapentinoids. (Source: WebMD Health)
Source: WebMD Health - June 14, 2019 Category: Consumer Health News Source Type: news

Epilepsy Drug Pregabalin (Lyrica) Tied to Higher Risk of Suicidal Behavior in Young Users
THURSDAY, June 13, 2019 -- A new study supports the notion that a drug used to control epilepsy and other disorders could make some young people more prone to suicide. The medicine, pregabalin (Lyrica), comes from a class of drugs called... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 13, 2019 Category: General Medicine Source Type: news

Pfizer announces top-line results from Phase 3 Trial of LYRICA ® (pregabalin) in primary generalized tonic-clonic seizures
Pfizer Inc. (NYSE: PFE) announced today that a Phase 3 study to assess the use of LYRICA® (pregabalin) as adjunctive therapy for epilepsy patients 5 to 65 years of age with primary generalized tonic-clonic (PGTC) seizures did not meet its primary endpoint. Treatment with LYRICA did not result in a statistically significant reduction in seizure frequency versus placebo. (Source: World Pharma News)
Source: World Pharma News - May 24, 2019 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Gabapentin and Pregabalin for Pain in Children, Adolescents Gabapentin and Pregabalin for Pain in Children, Adolescents
What is the current evidence for the safety and efficacy of gabapentin and pregabalin for neuropathic and postoperative pain in children and adolescents?Anesthesia & Analgesia (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 5, 2019 Category: Consumer Health News Tags: Anesthesiology Journal Article Source Type: news

Pregabalin/Lyrica reclassified to a class C drug
The move comes after Pregabalin/Lyrica was linked to 33 deaths in Northern Ireland in 2017. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - April 1, 2019 Category: Consumer Health News Source Type: news

Rescheduling of gabapentin and pregabalin to Schedule 3 Controlled Drugs from 1 April 2019
Gabapentin and Pregabalin will be reclassified to Schedule 3 Controlled Drugs (CDs) from 1 April 2019. (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - March 29, 2019 Category: Drugs & Pharmacology Source Type: news